Patents by Inventor Walter J. García-Ubbelohde

Walter J. García-Ubbelohde has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Polynucleotides encoding VNAR anti-cytokine domains
    Patent number: 9683035
    Abstract: The present invention concerns therapeutic compositions containing proteins that are the variable regions of IgNAR immunoglobulins, denominated vNAR, that specifically bind and neutralizes cytokines involved in a diversity of process such as inflammation and neovascularization, its ability to reach, bind, and neutralize the activity of one antigenic molecule localized in an immunoprivileged organs, are also described.
    Type: Grant
    Filed: July 25, 2016
    Date of Patent: June 20, 2017
    Assignee: LABORATORIOS SILANES, S.A. DE C.V.
    Inventors: Jorge F. Paniagua-Solís, María Teresa Mata-González, Walter J. García-Ubbelohde, Araceli Olguín-Jimenez, Alexei F. Licea-Navarro, Tanya A. Camacho-Villegas, Edna Sanchez-Castrejon
  • VHNAR ANTI-CYTOKINE DOMAINS
    Publication number: 20170037122
    Abstract: The present invention concerns therapeutic compositions containing proteins that are the variable regions of IgNAR immunoglobulins, denominated vNAR, that specifically bind and neutralizes cytokines involved in a diversity of process such as inflammation and neovascularization, its ability to reach, bind, and neutralize the activity of one antigenic molecule localized in an immunoprivileged organs, are also described.
    Type: Application
    Filed: July 25, 2016
    Publication date: February 9, 2017
    Inventors: Jorge F. Paniagua-Solís, María Teresa Mata-González, Walter J. García-Ubbelohde, Araceli Olguín-Jimenez, Alexei F. Licea-Navarro, Tanya A. Camacho-Villegas, Edna Sanchez-Castrejon
  • VNAR anti-cytokine domains
    Patent number: 9399677
    Abstract: The present invention concerns therapeutic compositions containing proteins that are the variable regions of IgNAR immunoglobulins, denominated vNAR, that specifically bind and neutralizes cytokines involved in a diversity of process such as inflammation and neovascularization, its ability to reach, bind, and neutralize the activity of one antigenic molecule localized in an immunoprivileged organs, are also described.
    Type: Grant
    Filed: July 17, 2013
    Date of Patent: July 26, 2016
    Assignee: LABORATORIES SILANES S.A. DE C.V.
    Inventors: Jorge F. Paniagua-Solís, María Teresa Mata-González, Walter J. García-Ubbelohde, Araceli Olguín-Jimenez, Alexei F. Licea-Navarro, Tanya A. Camacho-Villegas, Edna Sanchez-Castrejon
  • VHNAR ANTI-CYTOKINE DOMAINS
    Publication number: 20140044716
    Abstract: The present invention concerns therapeutic compositions containing proteins that are the variable regions of IgNAR immunoglobulins, denominated vNAR, that specifically bind and neutralizes cytokines involved in a diversity of process such as inflammation and neovascularization, its ability to reach, bind, and neutralize the activity of one antigenic molecule localized in an immunoprivileged organs, are also described.
    Type: Application
    Filed: July 17, 2013
    Publication date: February 13, 2014
    Applicant: LABORATORIOS SILANES, S.A. DE C.V.
    Inventors: Jorge F. Paniagua-Solís, María Teresa Mata-González, Walter J. García-Ubbelohde, Araceli Olguín-Jimenez, Alexei F. Lícea-Navarro, Tanya A. Camacho-Villegas, Edna Sanchez-Castrejon
  • Compositions of F(ab?)antibody fragments
    Patent number: 8512706
    Abstract: The present invention is directed to a pharmaceutical composition comprising F(ab?)2 antibody fragments that are preferably free from albumin and of whole antibodies and also substantially free of pyrogens, and an effective amount of a pharmaceutically acceptable carrier. It is also directed to a method for the production of a pharmaceutical composition comprising F(ab?)2 antibody fragments using scrum or blood plasma of a mammal that has been previously immunized as a source of antibodies. The serum or blood plasma is digested with an enzyme pepsin, followed by separation and purification until the pharmaceutical composition of F(ab?)2 fragments is free of albumin and complete antibodies, and substantially free of pyrogens.
    Type: Grant
    Filed: November 17, 2011
    Date of Patent: August 20, 2013
    Assignee: Instituto Bioclon, S.A. DE C.V.
    Inventors: Juan López De Silanes, Rita Guadalupe Mancilla Nava, Jorge F. Paniagua-Solís, Alejandro Alagon Cano, Walter J. García-Ubbelohde
  • VNAR anti-cytokine domains
    Patent number: 8496933
    Abstract: The present invention concerns therapeutic compositions containing proteins that are the variable regions of IgNAR immunoglobulins, denominated vNAR, that specifically bind and neutralizes cytokines involved in a diversity of process such as inflammation and neovascularization, its ability to reach, bind, and neutralize the activity of one antigenic molecule localized in an immunoprivileged organs, are also described.
    Type: Grant
    Filed: November 4, 2010
    Date of Patent: July 30, 2013
    Assignee: Laboratorios Silanes, S.A. de C.V.
    Inventors: Jorge F. Paniagua-Solís, María Teresa Mata-González, Walter J. García-Ubbelohde, Araceli Olguín-Jimenez, Alexei F. Licea-Navarro, Tanya A. Camacho-Villegas, Edna Sanchez-Castrejon
  • Pharmaceutical composition of F(ab?)antibody fragments and a process for the preparation thereof
    Patent number: 8075893
    Abstract: The present invention is directed to a pharmaceutical composition comprising F(ab?)2 antibody fragments that are preferably free from albumin and of whole antibodies and also substantially free of pyrogens, and an effective amount of a pharmaceutically acceptable carrier. It is also directed to a method for the production of a pharmaceutical composition comprising F(ab?)2 antibody fragments using serum or blood plasma of a mammal that has been previously immunized as a source of antibodies. The serum or blood plasma is digested with an enzyme pepsin, followed by separation and purification until the pharmaceutical composition of F(ab?)2 fragments is free of albumin and complete antibodies, and substantially free of pyrogens.
    Type: Grant
    Filed: December 2, 2008
    Date of Patent: December 13, 2011
    Assignee: Instituto Bioclon, S.A. de S.V.
    Inventors: Juan López De Silanes, Rita Guadalupe Mancilla Nava, Jorge F. Paniagua-Solís, Alejandro Alagon Cano, Walter J. García-Ubbelohde
  • VHNAR ANTI-CYTOKINE DOMAINS
    Publication number: 20110129473
    Abstract: The present invention concerns therapeutic compositions containing proteins that are the variable regions of IgNAR immunoglobulins, denominated vNAR, that specifically bind and neutralizes cytokines involved in a diversity of process such as inflammation and neovascularization, its ability to reach, bind, and neutralize the activity of one antigenic molecule localized in an immunoprivileged organs, are also described.
    Type: Application
    Filed: November 4, 2010
    Publication date: June 2, 2011
    Applicant: Laboratorios Silanes, S.A. de C.V.
    Inventors: JORGE F. PANIAGUA-SOLÍS, María Teresa MATA-GONZÁLEZ, Walter J. GARCÍA-UBBELOHDE, Araceli OLGUÍN-JIMENEZ, Alexei F. Licea-Navarro, Tanya A. Camacho-Villegas, Edna Sanchez-Castrejon